000906319 001__ 906319
000906319 005__ 20230307104044.0
000906319 0247_ $$2doi$$a10.3390/biomedicines10020441
000906319 0247_ $$2Handle$$a2128/33201
000906319 0247_ $$2pmid$$a35203649
000906319 0247_ $$2WOS$$aWOS:000763798500001
000906319 037__ $$aFZJ-2022-01369
000906319 082__ $$a570
000906319 1001_ $$0P:(DE-Juel1)165152$$aSevenich, Marc$$b0
000906319 245__ $$aPhage Display-Derived Compounds Displace hACE2 from Its Complex with SARS-CoV-2 Spike Protein
000906319 260__ $$aBasel$$bMDPI$$c2022
000906319 3367_ $$2DRIVER$$aarticle
000906319 3367_ $$2DataCite$$aOutput Types/Journal article
000906319 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1671602063_30681
000906319 3367_ $$2BibTeX$$aARTICLE
000906319 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000906319 3367_ $$00$$2EndNote$$aJournal Article
000906319 520__ $$aSevere respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly contagious beta-class coronavirus. Although vaccinations have shown high efficacy, the emergence of novel variants of concern (VOCs) has already exhibited traits of immune evasion. Thus, the development of tailored antiviral medications for patients with incomplete, inefficient, or non-existent immunization, is essential. The attachment of viral surface proteins to the cell surface is the first crucial step in the viral replication cycle, which for SARS-CoV-2 is mediated by the high affinity interaction of the viral trimeric spike with the host cell surface-located human angiotensin converting enzyme-2 (hACE2). Here, we used a novel and efficient next generation sequencing (NGS) supported phage display strategy for the selection of a set of SARS-CoV-2 receptor binding domain (RBD)-targeting peptide ligands that bind to the target protein with low µM to nM dissociation constants. Compound CVRBDL-3 inhibits the SARS-CoV-2 spike protein association to hACE2 in a concentration-dependent manner for pre- as well as post-complex formation conditions. Further rational optimization yielded a CVRBDL-3 based divalent compound, which demonstrated inhibitory efficacy with an IC50 value of 47 nM. The obtained compounds were not only efficient for the different spike constructs from the originally isolated “wt” SARS-CoV-2, but also for B.1.1.7 mutant trimeric spike protein. Our work demonstrates that phage display-derived peptide ligands are potential fusion inhibitors of viral cell entry. Moreover, we show that rational optimization of a combination of peptide sequences is a potential strategy in the further development of therapeutics for the treatment of acute COVID-19.
000906319 536__ $$0G:(DE-HGF)POF4-5244$$a5244 - Information Processing in Neuronal Networks (POF4-524)$$cPOF4-524$$fPOF IV$$x0
000906319 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000906319 7001_ $$0P:(DE-HGF)0$$aThul, Elena$$b1
000906319 7001_ $$0P:(DE-Juel1)180657$$aLakomek, Nils-Alexander$$b2$$ufzj
000906319 7001_ $$0P:(DE-HGF)0$$aKlünemann, Thomas$$b3
000906319 7001_ $$00000-0002-7041-9056$$aSchubert, Maren$$b4
000906319 7001_ $$00000-0001-6477-1785$$aBertoglio, Federico$$b5
000906319 7001_ $$00000-0001-5085-4010$$avan den Heuvel, Joop$$b6
000906319 7001_ $$00000-0002-8355-5524$$aPetzsch, Patrick$$b7
000906319 7001_ $$0P:(DE-Juel1)132012$$aMohrlüder, Jeannine$$b8$$ufzj
000906319 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b9$$eCorresponding author
000906319 773__ $$0PERI:(DE-600)2720867-9$$a10.3390/biomedicines10020441$$gVol. 10, no. 2, p. 441 -$$n2$$p441 -$$tBiomedicines$$v10$$x2227-9059$$y2022
000906319 8564_ $$uhttps://juser.fz-juelich.de/record/906319/files/biomedicines-10-00441-v2.pdf$$yOpenAccess
000906319 8767_ $$8102005$$92022-03-02$$d2022-09-14$$eAPC$$jZahlung erfolgt$$zOABLE
000906319 909CO $$ooai:juser.fz-juelich.de:906319$$pdnbdelivery$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire
000906319 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)165152$$aForschungszentrum Jülich$$b0$$kFZJ
000906319 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180657$$aForschungszentrum Jülich$$b2$$kFZJ
000906319 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132012$$aForschungszentrum Jülich$$b8$$kFZJ
000906319 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b9$$kFZJ
000906319 9131_ $$0G:(DE-HGF)POF4-524$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5244$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vMolecular and Cellular Information Processing$$x0
000906319 9141_ $$y2022
000906319 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-22
000906319 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-22
000906319 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000906319 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-22
000906319 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-08-22
000906319 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000906319 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-08-22
000906319 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000906319 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000906319 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-07T14:28:55Z
000906319 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-07T14:28:55Z
000906319 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-07T14:28:55Z
000906319 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000906319 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000906319 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-11
000906319 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-11
000906319 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000906319 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000906319 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000906319 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000906319 920__ $$lyes
000906319 9201_ $$0I:(DE-Juel1)IBI-7-20200312$$kIBI-7$$lStrukturbiochemie$$x0
000906319 980__ $$ajournal
000906319 980__ $$aVDB
000906319 980__ $$aUNRESTRICTED
000906319 980__ $$aI:(DE-Juel1)IBI-7-20200312
000906319 980__ $$aAPC
000906319 9801_ $$aAPC
000906319 9801_ $$aFullTexts